Tesla awards CEO Musk millions in shares valued at about US$29 billion
Tesla is awarding CEO Elon Musk 96 million shares of restricted stock valued at approximately US$29 billion, just six months after a judge ordered the company to revoke his massive pay package.
The electric vehicle maker said in a regulatory filing on Monday that Musk must first pay Tesla $23.34 per share of restricted stock that vests, which is equal to the exercise price per share of the 2018 pay package that was awarded to the company's CEO.
In December Delaware Chancellor Kathaleen St. Jude McCormick reaffirmed her earlier ruling that Tesla must revoke Musk's multibillion-dollar pay package. She found that Musk engineered the landmark pay package in sham negotiations with directors who were not independent.
At the time McCormick also rejected an equally unprecedented and massive fee request by plaintiff attorneys, who argued that they were entitled to legal fees in the form of Tesla stock valued at more than $5 billion. The judge said the attorneys were entitled to a fee award of $345 million.
The rulings came in a lawsuit filed by a Tesla stockholder who challenged Musk's 2018 compensation package.
That pay package carried a potential maximum value of about $56 billion, but that sum has fluctuated over the years based on Tesla's stock price.
Musk appealed the order in March. A month later Tesla said in a regulatory filing that it was creating a special committee to look at Musk's compensation as CEO.
In a letter to shareholders, Tesla's board said that Musk hasn't received 'meaningful compensation' for eight years, citing the 2012 CEO Performance Award that was last earned in 2017. The board argued that Musk deserves compensation because he's delivered 'transformative and unprecedented growth' that's 'translated into immense value generated for Tesla and all our shareholders.'
Musk has been one of the richest people in the world for several years.
Wedbush analyst Dan Ives feels Musk's stock award may alleviate some Tesla shareholder concerns.
'We believe this grant will now keep Musk as CEO of Tesla at least until 2030 and removes an overhang on the stock,' Ives wrote in a client note. 'Musk remains Tesla's big asset and this comp issue has been a constant concern of shareholders once the Delaware soap opera began.'
Tesla shares have plunged 25% this year, largely due to blowback over Musk's affiliation with President Donald Trump. But Tesla also faces intensifying competition from both the big Detroit automakers, and from China.
In its most recent quarter, Tesla reported that quarterly profits plunged from $1.39 billion to $409 million. Revenue also fell and the company fell short of even the lowered expectations on Wall Street.
Under pressure from shareholders last month, Tesla scheduled an annual shareholders meeting for November to comply with Texas state law.
A group of more than 20 Tesla shareholders, which have watched Tesla shares plummet, said in a letter to the company that it needed to at least provide public notice of the annual meeting.
Investors have grown increasingly worried about the trajection of the company after Musk had spent so much time in Washington this year, becoming one of the most prominent officials in the Trump administration in its bid to slash the size of the U.S. government.
Tesla's stock rose more than 2% in morning trading. Shares are down about 23% in the year to date.
By Michelle Chapman
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
30 minutes ago
- Globe and Mail
ITRM Reports Results
Key Points Non-GAAP EPS was ($0.13), missing the consensus estimate by $0.02 (non-GAAP), due to higher pre-commercialization spending. Research and development expenses fell 48.2% compared to Q2 2024, while general and administrative costs rose 121.1%, Research and development expenses were $1.0 million compared to $2.1 million for the same period in 2024, while general and administrative expenses increased from $1.9 million to $4.2 million, reflecting launch preparations. Cash runway is projected into 2026, with a $20.0 million milestone payment to Pfizer deferred until October 2029, reducing near-term cash pressure. These 10 stocks could mint the next wave of millionaires › Iterum Therapeutics Plc (NASDAQ:ITRM), an infectious disease biopharma company preparing to launch a new oral antibiotic for urinary tract infections, reported its results for the second quarter of 2025 on August 5, 2025. The key news in the release was its continued lack of revenue as it gears up for the first commercial sales of ORLYNVAH™, coupled with a larger operating loss driven by a jump in general and administrative costs. Reported non-GAAP loss per share came in at ($0.13), which was $0.02 below analyst expectations for non-GAAP EPS, while revenue (GAAP) was in line with estimates at zero. Overall, the quarter marked a pivotal transition phase, with significant expense increases for launch readiness but progress made in manufacturing, patent protection, and financial runway extension. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Company Overview and Recent Focus Iterum Therapeutics focuses on bringing new solutions to patients with serious infectious diseases, especially those where antibiotic resistance limits treatment options. Its most advanced product is ORLYNVAH™, an oral antibiotic tablet aimed at treating uncomplicated urinary tract infections (uUTIs), particularly cases caused by bacteria resistant to existing drugs. The company's recent efforts have targeted three areas: preparing for the first commercial launch of ORLYNVAH™, reinforcing patent protection to secure long-term value, and managing its financial position. Key factors for success include establishing commercial and distribution partnerships, navigating the regulatory landscape, and balancing operating costs to extend cash resources through launch. Highlights From the Quarter: Financial and Operational Developments The company reported no revenue in the quarter, which matches its pre-launch status and analyst forecasts. Non-GAAP EPS was a loss of $0.13, steeper than the anticipated $0.11 non-GAAP loss, largely due to a substantial increase in general and administrative (G&A) spending. This rise in G&A costs—from $1.9 million in the prior-year quarter to $4.2 million (GAAP)—was linked to investments in pre-commercialization work, such as market research and promotional strategy development. Research and development (R&D) expenses dropped sharply to $1.0 million (GAAP). Research and development expenses were $1.0 million compared to $2.1 million for the same period in 2024, as clinical trial activity wound down following the conclusion of the REASSURE Phase 3 trial for ORLYNVAH™. Total operating expenses (GAAP) climbed 39.1% year over year, to $5.5 million, with the G&A increase outweighing the R&D savings. The net loss, using Generally Accepted Accounting Principles (GAAP), was $6.5 million, greater than the $5.0 million GAAP net loss in Q2 2024. Operationally, Iterum put in place agreements to ensure manufacturing supply for ORLYNVAH™'s launch and expanded its intellectual property portfolio, securing a Canadian patent for its core antibiotic combination. The appointment of a new chief commercial officer signaled increased focus on market entry and execution. Iterum also finalized a commercialization agreement with EVERSANA to support U.S. sales, marketing, and distribution. The balance sheet reflected both ongoing cash burn and steps to strengthen the company's financial position. Cash and equivalents totaled $13.0 million as of June 30, 2025, and management indicated this is sufficient to support operations, including the commercial launch, into 2026, based on cash and cash equivalents as of March 31, 2025, together with amounts raised under the Registered Direct Offering and at-the-market offering program. Of note, a $20.0 million milestone payment due to Pfizer was deferred until October 2029, easing the company's near-term liquidity needs. At the end of the quarter, the company reported approximately 44.7 million shares outstanding, up meaningfully as new shares were issued to fund operations. About the Product Pipeline and Intellectual Property ORLYNVAH™ is an oral antibiotic tablet, or penem, formulated specifically for treating uncomplicated urinary tract infections in adult women when other oral options are limited or ineffective. The product stands out as the only oral penem approved by the U.S. Food and Drug Administration (FDA) and the first branded oral antibiotic in over 25 years for this indication. Iterum has built a robust patent portfolio, now extending to December 2039 in Canada, which helps protect its sulopenem/probenecid combination from generic competition. Looking Ahead: Management Outlook and Investor Watchpoints For FY2025 and beyond, management expects the existing cash balance, together with recent capital raises, to cover operational and commercialization activities into 2026. No detailed revenue or profit guidance was provided, as focus remains on completing the U.S. launch of ORLYNVAH™ in late August and laying the foundation for future sales. Other areas to monitor include expense trends—particularly in G&A as launch operations build out—and potential further equity raises given heightened cash needs ahead of revenue generation. Competitive developments will also be important, especially as other new antibiotics, such as from GlaxoSmithKline, move closer to market entry. ITRM does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,039%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025 JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Globe and Mail
33 minutes ago
- Globe and Mail
How major US stock indexes fared Tuesday, 8/5/2025
U.S. stock indexes slipped following the latest discouraging signal on the U.S. economy. The S&P 500 fell 0.5% Tuesday, coming off a whipsaw stretch where it followed its worst day since May with its best since May. The Dow Jones Industrial Average fell 0.1%, and the Nasdaq composite fell 0.7%. A weaker-than-expected report on activity for U.S. services businesses added to worries that President Donald Trump's tariffs may be hurting the economy. But hopes for coming cuts to interest rates by the Federal Reserve, along with a stream of stronger-than-expected profit reports from U.S. companies, helped keep the losses in check. On Tuesday: The S&P 500 fell 30.75 points, or 0.5%, to 6,299.19. The Dow Jones Industrial Average fell 61.90 points, or 0.1%, to 44,111.74. The Nasdaq composite fell 137.03 points, or 0.7%, to 20,916.55. The Russell 2000 index of smaller companies rose 13.37 points, or 0.6%, to 2,225.67. For the week: The S&P 500 is up 61.18 points, or 1%. The Dow is up 523.16 points, or 1.2%. The Nasdaq is up 266.42 points, or 1.3%. The Russell 2000 is up 58.89 points, or 2.7%. For the year: The S&P 500 is up 417.56 points, or 7.1%. The Dow is up 1,567.52 points, or 3.7%. The Nasdaq is up 1,605.76 points, or 8.3%. The Russell 2000 is down 4.49 points, or 0.2%.
Globe and Mail
an hour ago
- Globe and Mail
CCC Intelligent Solutions Announces Pricing of Secondary Offering of 30 Million Shares of Common Stock
CCC Intelligent Solutions Holdings Inc. (the 'Company') (NASDAQ: CCCS) today announced the pricing of the previously announced secondary offering of the Company's common stock (the 'Offering') by affiliates of Advent International, L.P. (the 'Selling Stockholders') at a price to the public of $9.89 per share. The Offering consists of 30,000,000 shares of the Company's common stock. The Offering is expected to close on or about August 7, 2025, subject to the satisfaction of customary closing conditions. The Offering consists entirely of shares of the Company's common stock to be sold by the Selling Stockholders, and the Company will not receive any proceeds from the sale of the shares being offered by the Selling Stockholders. Goldman Sachs & Co. LLC is acting as book running manager for the Offering. The Offering is being made pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-267793), which has been filed with the Securities and Exchange Commission ('SEC') and became effective on October 14, 2022. The Offering is being made only by means of a prospectus supplement and the accompanying base prospectus. You may get these documents for free, including the prospectus supplement, once available, by visiting EDGAR on the SEC website at Alternatively, copies of the prospectus supplement, once available, and the accompanying base prospectus may be obtained by contacting: Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectus-ny@ This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. ABOUT CCC INTELLIGENT SOLUTIONS CCC Intelligent Solutions Inc. (CCC), a subsidiary of CCC Intelligent Solutions Holdings Inc. (NASDAQ: CCCS), is a leading SaaS platform provider for the multi-trillion-dollar insurance economy, creating intelligent experiences for insurers, repairers, automakers, part suppliers, and more. The CCC Intelligent Experience (IX) Cloud™ platform, powered by proven AI and an innovative event-based architecture, connects more than 35,000 businesses to power customized applications and platforms for optimal outcomes and personalized experiences that just work. Through purposeful innovation and the strength of its connections, CCC technologies empower the people and industry relied upon to keep lives moving forward when it matters most. FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding the Offering, including the expected closing of the Offering. Such differences may be material. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, closing of the Offering on the anticipated terms or at all; market conditions; and the satisfaction of customary closing conditions related to the Offering; and other risks and uncertainties, including those included under the header 'Risk Factors' in our Form 10-K filed with the SEC on February 25, 2025, which can be obtained, without charge, at the SEC's website ( The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
